Associated Genetic Biomarkers
Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17) is a gene that encodes a protein that functions in B cell development and autoimmune response. The protein also functions in NF-kappaB and MAPK8/JNK activation. Missense mutations, silent mutations, frameshift insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
TNFRSF17 status serves as an inclusion eligibility criteria in 7 clinical trials, of which 6 are open and 1 is closed. Of the trials that contain TNFRSF17 status as an inclusion criterion, 1 is early phase 1 (1 open) and 6 are phase 1 (5 open).
Trials with TNFRSF17 status in the inclusion eligibility criteria most commonly target multiple myeloma .
The most frequent alterations to serve as inclusion eligibility criteria are TNFRSF17 Expression and TNFRSF17 Overexpression .
Cyclophosphamide, fludarabine, idecabtagene vicleucel, autologous anti-bcma-car-expressing cd4+/cd8+ t-lymphocytes fcarh143, and chimeric antigen receptor t-cells are the most frequent therapies in trials with TNFRSF17 as an inclusion criteria .
Significance of TNFRSF17 in Diseases
Multiple Myeloma +
TNFRSF17 is an inclusion criterion in 7 clinical trials for multiple myeloma, of which 6 are open and 1 is closed. Of the trials that contain TNFRSF17 status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open) and 6 are phase 1 (5 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.